Type of information: Research agreement
Compound: engineered adeno-associated virus (vgAAV)
Company: ViGeneron (DE) Daiichi-Sankyo (Japan)
Therapeutic area: Ophthalmological diseases
Type agreement: research
Action mechanism: gene therapy.
- On January 18, 2021, ViGeneron announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction of target cells via intravitreal injection that allows efficient lateral spreading and minimizes the risk of collateral damage caused by conventional subretinal injection.
- Under the agreement, Daiichi Sankyo and ViGeneron will jointly conduct the first stage research and Daiichi Sankyo will have the option to negotiate a follow-on collaboration agreement for an undisclosed therapeutic target in the highly prevalent eye disease. Financial terms of the collaboration are not disclosed.
- Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.
Financial terms: Financial terms of the collaboration are not disclosed.